

GABY Announces Changes to Board of Directors and Appoints Maureen Putman as Chief Marketing Advisor

SANTA ROSA, CA and CALGARY, ALBERTA / ACCESSWIRE / March 9, 2020 / GABY Inc. ("GABY" or the "Company") (CSE:GABY) (OTCQB:[GABLF](#)), a California based consumer packaged goods company using cannabinoids (whole plant, isolates and distillates) as foundational ingredients in a range of wellness oriented branded products sold in the regulated cannabis sector in California as well as the mainstream grocery channel across the United States, today announced two changes to its board of directors:

Charles Mannix is leaving the GABY Board of Directors due to an immediate need to focus on other pressing business matters that require his full attention. Mr. Mannix continues to be a shareholder and strong supporter of GABY's management, board and strategy.

Maureen Putman has agreed to take on a more active role in GABY consulting as Chief Marketing Advisor. As such Maureen is resigning from the Board of Directors to concentrate on sales, marketing and brand building for GABY as we ramp up sales in the months to come.

"I would like to thank Charles and Maureen for their contribution to the GABY board of directors and am gratified that even though they are leaving the board they both remain supporters of GABY and in Maureen's case will be even more involved in the operations", said Margot Micallef, Founder, President and CEO of GABY.

"I have enjoyed my involvement with the GABY board of directors and have a high degree of respect for the members with whom I have served. I regret that other matters requiring my full attention are pulling me away from GABY but hope to one day again be of service to the Company", said Charles Mannix.

"My increasing involvement with GABY's marketing activities makes my role as a board member of GABY more challenging" said Maureen Putman. She continued: "I am therefore resigning from the Board to better serve GABY as we ramp up in the year to come. Like Charles, I too have enjoyed working with the high calibre board members that Ms. Micallef has attracted to the board".

"Maureen's involvement with large CPG companies from early start up to mature operating company serves GABY well and we are grateful to have her increasing involvement with our company" concluded Margot Micallef.

It is not expected that the Company will fill these vacancies at this time.

GABY is a U.S.-focused, consumer packaged goods company operating a *family of brands* in the cannabis industry and in the mainstream grocery channel. Through its subsidiaries GABY indirectly holds licenses and permits issued by the California Department of Health, the

California Bureau of Cannabis Control and the County of Sonoma for manufacturing and distribution and license applications pending for cultivation and nursery licenses with the California Department of Food and Agriculture. With these licenses and permits to operate in the cannabis channel, and its existing infrastructure of major retailers and an extensive broker and distribution network in the mainstream channel, GABY has successfully brought a number of its proprietary, acquired and third-party brands to market in both the licensed and mainstream market.

Margot and her sister Gabriella co-founded GABY after Gabriella received a dire cancer diagnosis which spurred the sisters to prolong Gabriella's life through a holistic approach to health. Today, GABY is a wellness company with a diverse range of products that use cannabis, hemp and hemp derived cannabinoids to address a variety of dietary and health concerns. Although Gabriella ultimately passed away from her illness, she lived exponentially longer than doctors predicted. Her memory and passion live on through GABY's mission: to empower people to live healthy lives without compromise.

GABY's shares trade on the Canadian Securities Exchange ("CSE") under the symbol "GABY" and on the OTCQB under the symbol "GABLF". For more information, visit www.GABYInc.com

For further inquiries, please contact:

General

Margot Micallef, Founder, President & CEO or Investor Relations at IR@GABYinc.com or 800-674-2239.

Media

Colin Trethewey, APR
colin@prmedianow.com
813-480-1354

Disclaimer and Forward-Looking Information

The CSE does not accept responsibility for the adequacy or accuracy of this release. Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, certain of which are beyond the control of the Company. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward looking statements include, but are not limited to, the release of Lulu's Chocolates Consideration Shares and 2Rise Naturals Consideration Shares pursuant to the Lulu's Chocolate Escrow Agreement and 2Rise Naturals

Escrow Agreement, respectively. The Company assumes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Each of KJM Data and Research Inc., Sonoma Pacific Distribution, Inc., Lulu's Chocolate and 2Rise Naturals are subsidiaries of GABY. Each of these subsidiaries hold cannabis licenses in either the State of California or the State of Arizona. Unlike in Canada which has Federal legislation uniformly governing the cultivation, distribution, sale and possession of medical cannabis under the Cannabis Act (Federal), readers are cautioned that in the United States ("U.S."), cannabis is largely regulated at the State level. Cannabis is legal in the State of California and has been legalized for medicinal use in the State of Arizona, however cannabis remains illegal under U.S. federal laws. Notwithstanding the permissive regulatory environment of cannabis at the State level, cannabis continues to be categorized as a controlled substance under the Controlled Substances Act in the U.S. and as such, cannabis-related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. To the knowledge of the Company, the businesses operated by each of GABY's subsidiaries are conducted in a manner consistent with the State law of California or Arizona, as applicable, and are in compliance with regulatory and licensing requirements applicable in the State of California or Arizona, respectively. However, readers should be aware that strict compliance with State laws with respect to cannabis will neither absolve GABY, or its subsidiaries of liability under U.S. federal law, nor will it provide a defense to any federal proceeding in the U.S. which could be brought against any of GABY, or its subsidiaries. Any such proceedings brought against GABY, or its subsidiaries may materially adversely affect the Company's operations and financial performance generally in the U.S. market specifically.

Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.